LONQUEX® (lipegfilgrastim)

This information is only for patients who have been prescribed LONQUEX®

LONQUEX® is a medicine used to reduce the duration of neutropenia (low levels of neutrophils, a type of white blood cell) and the occurrence of febrile neutropenia (neutropenia with fever) in adult cancer patients receiving cytotoxic chemotherapy.

Cytotoxic chemotherapy (medicines that kill fast growing cells) commonly causes neutropenia because in addition to cancer cells, it also kills other fast-growing cells such as neutrophils, leaving the patient at risk of infections.

Lipegfilgrastim is the active substance in LONQUEX®.


How to inject LONQUEX® using the prefilled syringe:


Please read your patient information leaflet carefully before you start using this medicine because it contains important information for you, including step by step instructions on how to administer your LONQUEX® injection. You should not inject yourself until you have been trained by your doctor or nurse. You should also contact them if you have any further questions.


Further information and support

The patient information leaflet can be downloaded from the European Medicines Agency (EMA) website and you can contact Teva with any question about this medicine that you may have.

Patient Information Leaflet

Download from EMA

For questions about your medicine contact Teva

Contact us

Life Effects™

Living with one or more chronic conditions affects your life in so many ways. The only people who really know what you are going through are those who have faced the same challenges. With that in mind we have created Life Effects™, an initiative shaped by patients for patients.

Discover more Life Effects™

If you experience any side effects (adverse events), talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. This will allow quick identification of safety information. You can help by reporting any side effects you may experience. See www.hpra.ie for how to report side effects. Side effects may also be reported directly to Teva using our online form.

Date of preparation: July 2021
Reference: COB-IE-NP-00058